Ⅰ期非小细胞肺癌术后高危复发风险预测标志物的研究进展

Advances in molecular markers to predict the risk of postoperative high-risk recurrence of stageⅠnon-small cell lung cancer

Ⅰ期非小细胞肺癌(non-small cell lung cancer,NSCLC)的首选治疗方案为手术,然而仍有部分患者死于术后复发。近些年来,以基因相关预后标志物如基因表达谱、DNA甲基化;循环相关的预后标志物如循环肿瘤细胞(circulating tumor cells,CTCs)、循环的无细胞核酸[循环肿瘤DNA(circulating tumor DNA,ctDNA)和微小RNA(microRNA,miRNA)];免疫相关预后因子如程序性死亡受体配体1(programmed death-ligand 1,PD-L1)以及肿瘤突变负荷(tumor mutational burden,TMB)等为代表的分子标志物的发展为Ⅰ期NSCLC术后复发风险的预测提供了一个新的方向。本文概述了与Ⅰ期NSCLC术后高危复发风险相关的分子标志物研究进展,总结了这些分子标志物对判定Ⅰ期NSCLC术后高危复发风险的意义。

Surgical resection is the first choice for stage I non-small cell lung cancer(NSCLC)while the vast majority of patients still die from postoperative tumor recurrence.In recent years,the development of molecular markers represented by gene-related prognostic markers such as gene expression profiles and DNA methylation.Circulating prognostic markers such as circulating tumor cells(CTCs),circulating cell-free nucleic acids[circulating tumor DNA(ctDNA)and microRNA(miRNA)],immune-related prognostic factors such as programmed death-ligand 1(PD-L1)and tumor mutational burden(TMB)provide a new direction for predicting the risk of recurrence after stage I NSCLC.This article reviews the research progress of molecular markers related to the high-risk recurrence risk of stage I non-small cell lung cancer after surgery,and summarizes the significance of these molecular markers in determining the postoperative high-risk recurrence risk of stage I NSCLC.